ABVC BioPharma, Inc. (NASDAQ: ABVC) announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, revealing a transformative year with substantial balance sheet growth. Total assets increased to $21,062,203, a 179% year-over-year increase from $7,539,907 in 2024. Net property and equipment rose to $12,835,409 from $511,088, primarily driven by strategic land acquisitions in Asia. The company reported that title transitions to ABVC and its subsidiary are in process.
As of December 31, 2025, the company reported total assets of $21.06 million, property and equipment of $12.84 million, operating lease right-of-use assets of $1.91 million, and long-term investments of $1.88 million. Management believes the fiscal year 2025 represents a structural strengthening of the company's balance sheet and asset foundation.
ABVC has strategically licensed its core drug programs to subsidiaries and related parties: CNS pipeline to AiBtl BioPharma, oncology programs to OncoX BioPharma, and ophthalmology programs to ForSeeCon Eye Corporation. Under this structure, subsidiaries handle clinical development while ABVC reduces direct cash burn exposure and retains licensing economics and equity participation. This model separates development risk from long-term value participation while preserving upside and mitigating capital intensity.
In parallel, the company is strengthening its long-term infrastructure positioning in Asia through strategic land asset acquisitions. The Longtan District property in Taoyuan, covering 5,995.41 square meters, was valued at $4.6 million as of December 31, 2025. The land is held as a strategic reserve asset with flexible future use potential, including healthcare-related applications. The company has adopted a disciplined "land-first, development-later" approach.
The Puli Township property in Nantou, covering 69,230.90 square meters, was appraised at approximately $8.0 million as of January 30, 2026. The development plan focuses on establishing a medicinal plant cultivation base, supporting pharmaceutical supply chain localization, creating an agricultural-biotech integration platform, and developing value-added processing infrastructure. Projected annual cultivation and processing output value is estimated between $60,000 to $360,000, depending on processing depth.
This potential increase in fixed and real assets reflects ABVC's strategic evolution from a purely IP-driven biotech structure toward a hybrid model combining intellectual property, licensing revenue potential, equity participation in development subsidiaries, and tangible long-term physical assets.
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. The company utilizes in-licensed technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. More detailed information about the company is set forth in its filings with the SEC, including the Annual Report on Form 10-K, available at http://www.sec.gov.
